Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 18/20 | 0.59 |
| ▸ | CDK4 | P11802 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CCND1 | P24385 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5744857 | 1.00 | CTSK (0.59) | CTSKCDK4CCNA2CCND1CDK2 | |
| SCHEMBL5745249 | 0.97 | CTSK (0.56) | CTSKCDK4CCNA2CCND1CDK2 | |
| SCHEMBL5741769 | 0.92 | CTSK (0.54) | CTSKCTSLCTSS | |
| SCHEMBL5743571 | 0.92 | CTSK (0.54) | CTSKCTSLCTSS | |
| SCHEMBL6523315 | 0.92 | CTSK (0.54) | CTSKCTSLCTSS | |
| SCHEMBL5741733 | 0.92 | CTSK (0.54) | CTSKCTSLCTSS | |
| SCHEMBL6520079 | 0.92 | CTSK (0.54) | CTSKCTSLCTSS | |
| SCHEMBL5741740 | 0.91 | CTSK (0.53) | CTSK | |
| SCHEMBL5741918 | 0.91 | CTSK (0.53) | CTSK | |
| SCHEMBL5744875 | 0.90 | CTSK (0.49) | CTSKCTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1358183-B1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| US-20050070598-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2005-03-31 | — | — | US | disclosed |
| US-20040229915-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2004-11-18 | — | — | US | disclosed |
| EP-1358183-A2 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2003-11-05 | — | — | EP | disclosed |
| US-20030186962-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2003-10-02 | — | — | US | disclosed |
| WO-2002088106-A2 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186962-A1 | Cysteine protease inhibitors | C1R, CTSS, CTSZ | CTSK 4/4885CDK4 1320/4885CCNA2 867/4885 |
| US-20050070598-A1 | Cysteine protease inhibitors | CTRL, CTSZ, CTSS | CTSK 5/4885CDK4 740/4885CCNA2 1203/4885 |
| US-20040229915-A1 | Cysteine protease inhibitors | C1R, CTRL, CTSK | CTSK 3/4885CDK4 1659/4885CCNA2 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.